In order to solve the national tuberculosis control drug supply and patient demand, ensure the continuous supply of anti-tuberculosis drugs in China, promote the healthy development of China's anti-tuberculosis drug companies, and promote the effective implementation of China's tuberculosis control strategy, on the morning of December 24, 2016, China Disease Prevention Liu Jianjun, Deputy Director of the Control Center, Chairman of the Chinese Tuberculosis Association, Wang Lixia, Director of the Tuberculosis Prevention and Control Center of the Chinese Center for Disease Control and Prevention, Vice Chairman of the Chinese Tuberculosis Association, Cheng Shiming, Secretary-General of the Chinese Tuberculosis Association, Shanghai Fosun Pharmaceutical (Group) Wu Yifang, President and CEO of Co., Ltd. (hereinafter referred to as "Fosun Pharma"), Wang Donghua, Vice President of Fosun Pharma, and Yang Bo, General Manager of Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenyang Hongqi"), a member company of Fosun Pharma, etc. Shenyang Hongqi jointly unveiled the "China Anti-tuberculosis Drug Supply Coordination Reserve" of the China National Tuberculosis Association.
Cheng Shiming, secretary-general of the China Tuberculosis Association, read the "Letter from the China Tuberculosis Association on Establishing a Coordination and Reserve Bank of Anti-tuberculosis Drug Supply" from disease control institutions (tuberculosis prevention and control institutions) and medical and health institutions in all provinces (autonomous regions and municipalities) across the country. More than 80 people including leaders and experts and employees of Shenyang Hongqi attended the unveiling ceremony.
After the unveiling ceremony, the leaders and experts at the meeting visited the Shenyang Hongqi anti-tuberculosis drug supply coordination reserve. All kinds of first-line anti-tuberculosis drugs are stored neatly in the warehouse.
Leaders inspect the reserve
Over the past year, the China National Tuberculosis Association has conducted research on the supply of anti-tuberculosis drugs in my country, and after discussing with some provincial CDCs in my country, combined with the needs of my country's tuberculosis prevention and control, it plans to establish an anti-tuberculosis drug supply coordination reserve. Fosun Pharma and its member company Shenyang Hongqi responded positively. With the active participation and support of all employees, they raised more than 20 million yuan of funds to establish a coordinated reserve bank for the supply of anti-tuberculosis drugs.
This is the first reserve bank initiated by the my country National Tuberculosis Association, guided by the Chinese anti-tuberculosis expert group, and self-raised by the manufacturer. The China Antituberculosis Association will continue to support and cooperate in the areas of expert team construction, drug Internet supply management system construction, and drug supply coordination. The China Anti-tuberculosis Association stated that it hopes that the anti-tuberculosis drug supply coordination reserve will operate in accordance with market rules, with a bidding procurement mechanism as a strong support, promote the healthy development of my country's anti-tuberculosis drug companies, and benefit my country's anti-tuberculosis drug companies and tuberculosis patients.
The establishment of China’s anti-tuberculosis drug supply coordination reserve is to thoroughly implement the spirit of the “Three Science and Technology Conferences” held in Beijing this year. The China National Tuberculosis Association, Fosun Pharma and its member companies Shenyang Hongqi and other units are driving innovation in tuberculosis control in my country. The fruits of development. Following the China National Tuberculosis Public Welfare Fund-Tuberculosis Poverty Relief "Double Thousand Action" project launched this year, this initiative will not only provide guarantees for the availability of my country’s first-line anti-tuberculosis drugs, but will also wait until the unit’s anti-tuberculosis drugs are approved by the World Health Organization’s PQ (Prequalification ) After certification, it will also be able to provide first-line anti-tuberculosis drugs to the "BRIC" low- and middle-income countries and some countries such as Africa, to go abroad and into the world.
This is another important strategic cooperation between the China National Tuberculosis Association and Fosun Pharma and its member company Shenyang Hongqi, which has brought new gospel to the treatment and rescue of thousands of tuberculosis patients in my country and around the world.
Group photo of guests